FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2894963341> ?p ?o ?g. }

• W2894963341 endingPage "55" @default.
• W2894963341 startingPage "47" @default.
• W2894963341 abstract "BackgroundCancer treatment is based on tumor staging. Curative intent is only applied to localized tumors. Recent studies show that oligometastatic patients who have limited number of metastases may benefit from metastasis-directed local treatments to achieve long-term survival. However, mechanisms underlying oligometastatic to polymetastatic progression remains elusive.MethodsThe effects of miR-200c and Sec23a on tumor metastasis were verified both in vitro and in vivo. The secretome changes were detected by mass spectrometry.FindingsWe established a pair of homologous lung-metastasis derived oligometastatic and polymetastatic cell lines from human melanoma cancer cell line M14. Using the two cell lines, we have identified Sec23a, a gene target of miR-200c, suppresses miR-200c augmented oligometastatic to polymetastatic progression via its secretome. Firstly, miR-200c over-expression and Sec23a interference accelerated oligometastatic to polymetatic progression. Secondly, Sec23a functions downstream of miR-200c. Thirdly, mass spectrometric analysis of the secretory protein profile suggests that Sec23a-dependent secretome may impact metastatic colonization by modifying tumor microenvironment. Fourthly, the survival analysis using The Cancer Genome Atlas database shows Sec23a as a favorable prognostic marker for skin cutaneous melanoma, supporting the clinical relevance of our findings.InterpretationThe finding that Sec23a is a suppressor of oligometastatic to polymetastatic progression has clinical implications. First, it provides a new theoretical framework for the development of treatments that prevent oligometastasis to polymetastasis. Second, Sec23a may be used as a favorable prognostic marker for the selection of patients with stable oligometastatic disease for oligometastasis-based local therapies of curative intent.FundNational Natural Science Foundations of China." @default.
• W2894963341 created "2018-10-12" @default.
• W2894963341 creator A5025233131 @default.
• W2894963341 creator A5025642483 @default.
• W2894963341 creator A5030902395 @default.
• W2894963341 creator A5038634026 @default.
• W2894963341 creator A5039962884 @default.
• W2894963341 creator A5046453107 @default.
• W2894963341 creator A5056920431 @default.
• W2894963341 creator A5064376338 @default.
• W2894963341 creator A5087725251 @default.
• W2894963341 date "2018-11-01" @default.
• W2894963341 modified "2023-10-14" @default.
• W2894963341 title "Sec23a mediates miR-200c augmented oligometastatic to polymetastatic progression" @default.
• W2894963341 cites W1492262148 @default.
• W2894963341 cites W1603477068 @default.
• W2894963341 cites W1798411163 @default.
• W2894963341 cites W1965842207 @default.
• W2894963341 cites W1970637953 @default.
• W2894963341 cites W1974725481 @default.
• W2894963341 cites W1980554703 @default.
• W2894963341 cites W1980648331 @default.
• W2894963341 cites W1981144776 @default.
• W2894963341 cites W1985211287 @default.
• W2894963341 cites W1986429697 @default.
• W2894963341 cites W2005125776 @default.
• W2894963341 cites W2011727356 @default.
• W2894963341 cites W2033052459 @default.
• W2894963341 cites W2033520317 @default.
• W2894963341 cites W2035070743 @default.
• W2894963341 cites W2069756768 @default.
• W2894963341 cites W2070924960 @default.
• W2894963341 cites W2085317499 @default.
• W2894963341 cites W2087869013 @default.
• W2894963341 cites W2089645605 @default.
• W2894963341 cites W2090749716 @default.
• W2894963341 cites W2093516745 @default.
• W2894963341 cites W2103623995 @default.
• W2894963341 cites W2105368875 @default.
• W2894963341 cites W2106755681 @default.
• W2894963341 cites W2108994302 @default.
• W2894963341 cites W2111832790 @default.
• W2894963341 cites W2119894822 @default.
• W2894963341 cites W2119963920 @default.
• W2894963341 cites W2138885372 @default.
• W2894963341 cites W2139970219 @default.
• W2894963341 cites W2143207688 @default.
• W2894963341 cites W2143707736 @default.
• W2894963341 cites W2148894885 @default.
• W2894963341 cites W2157251796 @default.
• W2894963341 cites W2160615924 @default.
• W2894963341 cites W2162659150 @default.
• W2894963341 cites W2166459387 @default.
• W2894963341 cites W2168325971 @default.
• W2894963341 cites W2195735320 @default.
• W2894963341 cites W2341344950 @default.
• W2894963341 cites W2491066783 @default.
• W2894963341 cites W2557751991 @default.
• W2894963341 cites W2752846017 @default.
• W2894963341 cites W2775321189 @default.
• W2894963341 cites W2801468242 @default.
• W2894963341 cites W4231096603 @default.
• W2894963341 doi "https://doi.org/10.1016/j.ebiom.2018.10.002" @default.
• W2894963341 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6284370" @default.
• W2894963341 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30301603" @default.
• W2894963341 hasPublicationYear "2018" @default.
• W2894963341 type Work @default.
• W2894963341 sameAs 2894963341 @default.
• W2894963341 citedByCount "19" @default.
• W2894963341 countsByYear W28949633412020 @default.
• W2894963341 countsByYear W28949633412021 @default.
• W2894963341 countsByYear W28949633412022 @default.
• W2894963341 countsByYear W28949633412023 @default.
• W2894963341 crossrefType "journal-article" @default.
• W2894963341 hasAuthorship W2894963341A5025233131 @default.
• W2894963341 hasAuthorship W2894963341A5025642483 @default.
• W2894963341 hasAuthorship W2894963341A5030902395 @default.
• W2894963341 hasAuthorship W2894963341A5038634026 @default.
• W2894963341 hasAuthorship W2894963341A5039962884 @default.
• W2894963341 hasAuthorship W2894963341A5046453107 @default.
• W2894963341 hasAuthorship W2894963341A5056920431 @default.
• W2894963341 hasAuthorship W2894963341A5064376338 @default.
• W2894963341 hasAuthorship W2894963341A5087725251 @default.
• W2894963341 hasBestOaLocation W28949633411 @default.
• W2894963341 hasConcept C121608353 @default.
• W2894963341 hasConcept C126322002 @default.
• W2894963341 hasConcept C143998085 @default.
• W2894963341 hasConcept C2777658100 @default.
• W2894963341 hasConcept C2779013556 @default.
• W2894963341 hasConcept C2779256057 @default.
• W2894963341 hasConcept C502942594 @default.
• W2894963341 hasConcept C71924100 @default.
• W2894963341 hasConceptScore W2894963341C121608353 @default.
• W2894963341 hasConceptScore W2894963341C126322002 @default.
• W2894963341 hasConceptScore W2894963341C143998085 @default.
• W2894963341 hasConceptScore W2894963341C2777658100 @default.
• W2894963341 hasConceptScore W2894963341C2779013556 @default.
• W2894963341 hasConceptScore W2894963341C2779256057 @default.

• next